TY - JOUR
T1 - Assessment and management of heart failure in patients with chronic kidney disease
AU - Guaricci, Andrea Igoren
AU - Sturdà, Francesca
AU - Russo, Roberto
AU - Basile, Paolo
AU - Baggiano, Andrea
AU - Mushtaq, Saima
AU - Fusini, Laura
AU - Fazzari, Fabio
AU - Bertandino, Fulvio
AU - Monitillo, Francesco
AU - Carella, Maria Cristina
AU - Simonini, Marco
AU - Pontone, Gianluca
AU - Ciccone, Marco Matteo
AU - Grandaliano, Giuseppe
AU - Vezzoli, Giuseppe
AU - Pesce, Francesco
PY - 2024
Y1 - 2024
N2 - Heart failure (HF) and chronic kidney disease (CKD) are two pathological conditions with a high prevalence in the general population. When they coexist in the same patient, a strict interplay between them is observed, such that patients affected require a clinical multidisciplinary and personalized management. The diagnosis of HF and CKD relies on signs and symptoms of the patient but several additional tools, such as blood-based biomarkers and imaging techniques, are needed to clarify and discriminate the main characteristics of these diseases. Improved survival due to new recommended drugs in HF has increasingly challenged physicians to manage patients with multiple diseases, especially in case of CKD. However, the safe administration of these drugs in patients with HF and CKD is often challenging. Knowing up to which values of creatinine or renal clearance each drug can be administered is fundamental. With this review we sought to give an insight on this sizable and complex topic, in order to get clearer ideas and a more precise reference about the diagnostic assessment and therapeutic management of HF and CKD.
AB - Heart failure (HF) and chronic kidney disease (CKD) are two pathological conditions with a high prevalence in the general population. When they coexist in the same patient, a strict interplay between them is observed, such that patients affected require a clinical multidisciplinary and personalized management. The diagnosis of HF and CKD relies on signs and symptoms of the patient but several additional tools, such as blood-based biomarkers and imaging techniques, are needed to clarify and discriminate the main characteristics of these diseases. Improved survival due to new recommended drugs in HF has increasingly challenged physicians to manage patients with multiple diseases, especially in case of CKD. However, the safe administration of these drugs in patients with HF and CKD is often challenging. Knowing up to which values of creatinine or renal clearance each drug can be administered is fundamental. With this review we sought to give an insight on this sizable and complex topic, in order to get clearer ideas and a more precise reference about the diagnostic assessment and therapeutic management of HF and CKD.
KW - Biomarkers
KW - Cardio-renal syndrome
KW - Chronic kidney disease
KW - Guidelines-directed medical therapy
KW - Heart failure
KW - Biomarkers
KW - Cardio-renal syndrome
KW - Chronic kidney disease
KW - Guidelines-directed medical therapy
KW - Heart failure
UR - http://hdl.handle.net/10807/303643
U2 - 10.1007/s10741-023-10346-x
DO - 10.1007/s10741-023-10346-x
M3 - Article
SN - 1382-4147
VL - 29
SP - 379
EP - 394
JO - Heart Failure Reviews
JF - Heart Failure Reviews
ER -